Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.48 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015191 | 0.92 | NTRK1 (0.48) | NTRK1YTHDC1NTRK3DYRK1A | |
| SCHEMBL4013301 | 0.87 | FLT3 (0.51) | NTRK3DYRK1AGPR17FLT3P2RY2 | |
| SCHEMBL4008126 | 0.86 | NTRK1 (0.44) | NTRK1DYRK1AGPR17P2RY2 | |
| SCHEMBL4013332 | 0.82 | GPR17 (0.40) | NTRK1GPR17P2RY2 | |
| SCHEMBL4008006 | 0.82 | YTHDC1 (0.45) | NTRK1YTHDC1DYRK1A | |
| SCHEMBL4009643 | 0.82 | TDP1 (0.38) | GPR17P2RY2 | |
| SCHEMBL4008915 | 0.80 | NTRK1 (0.52) | NTRK1YTHDC1 | |
| SCHEMBL4005400 | 0.80 | APEX1 (0.46) | NTRK1YTHDC1DYRK1A | |
| SCHEMBL4010010 | 0.79 | GPR17 (0.37) | GPR17P2RY2 | |
| SCHEMBL4013454 | 0.79 | GPR17 (0.37) | GPR17P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NTRK1 1342/4885YTHDC1 4321/4885NTRK3 822/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NTRK1 1376/4885YTHDC1 4416/4885NTRK3 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.